Credit score: Pixabay/CC0 Public Area
Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medicines which are more and more prescribed for sufferers with sort 2 diabetes and congestive coronary heart failure. Studies of GLP-1RA–related acute kidney damage (AKI) have emerged, however the danger of GLP-1RA–related AKI amongst sufferers on anti-cancer medicine is unclear.
Surprisingly, new analysis means that taking GLP-1RA is just not related to an elevated danger of AKI in sufferers receiving anti-cancer therapies. The findings had been offered at ASN Kidney Week 2024 October 23–27.
For the examine, investigators analyzed medical information of sufferers who had been handled with anti-cancer medicines together with cytotoxic, focused immunotherapies over a one-year interval.
Amongst 14,783 sufferers, 9% had been handled with a GLP-1RA whereas taking anti-cancer medicine. AKI occurred in 7.2% of these uncovered to GLP-1RA versus 6.4% of these with no GLP-1RA publicity.
“Given the cardiovascular and anti-diabetic advantages of GLP-IRA, we propose that these brokers could be safely continued throughout administration of anti-cancer remedy,” mentioned corresponding creator Swetha Rani Kanduri, MD, of Ochsner Well being.
“We invite potential research to additional elaborate on the results of GLP1-RA in sufferers with most cancers.”
Extra info:
Examine: “Publicity to Glucagon Like Peptide 1 Receptor Agonists (GLP-1RA) Does Not Improve the Danger of AKI Related to Anti-Most cancers Remedy”
Supplied by
American Society of Nephrology
Quotation:
Do sure diabetes medicine improve the danger of acute kidney damage in sufferers taking anti-cancer therapies? (2024, October 25)
retrieved 25 October 2024
from https://medicalxpress.com/information/2024-10-diabetes-drugs-acute-kidney-injury.html
This doc is topic to copyright. Aside from any truthful dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.
